Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBD Mind Restore is a multi-ingredient dietary supplement formulated to support cognitive function, mental clarity, and stress management. The primary active component is cannabidiol (CBD), a non-psychoactive phytocannabinoid derived from the hemp plant (*Cannabis sativa*). CBD interacts with the endocannabinoid system (ECS) by acting as a negative allosteric modulator of the cannabinoid receptor 1 (CB1) and an inverse agonist of the cannabinoid receptor 2 (CB2), while also functioning as an agonist at the serotonin 5-HT1A receptor. These interactions contribute to its reported anxiolytic and neuroprotective properties. The formulation typically includes nootropic and calming agents such as L-theanine, gamma-aminobutyric acid (GABA), and magnesium, which work synergistically to modulate inhibitory neurotransmission and promote relaxation without sedation. It is marketed as a nutraceutical for individuals seeking to enhance focus and mitigate the physiological effects of daily stress.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CBD Mind Restore.